Patents by Inventor Tomohiro UMEDA

Tomohiro UMEDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for nasal administration
    Patent number: 11583494
    Abstract: The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 21, 2023
    Assignee: MEDILABO RFP, INC.
    Inventors: Takami Tomiyama, Tomohiro Umeda
  • PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES
    Publication number: 20220125782
    Abstract: A technique of administering rifampicin over an extended period of time, with reduced side effects. A medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 28, 2022
    Inventors: Takami Tomiyama, Tomohiro Umeda, Toru Kumagai
  • PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION
    Publication number: 20200129426
    Abstract: The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 30, 2020
    Inventors: Takami TOMIYAMA, Tomohiro UMEDA